The Food and Drug Administration today is alerting health care professionals and patients about early results of new studies for Paxil (paroxetine) suggesting that the drug increases the risk for birth defects, particularly heart defects, when women take it during the first three months of pregnancy. Paxil is approved for the treatment of depression and several other psychiatric disorders. FDA is currently gathering additional data and waiting for the final results of the recent studies in order to better understand the higher risk for birth defects that has been seen with Paxil.
Dec. 8 - FDA Advising of Risk of Birth Defects with Paxil
Thursday, December 8, 2005
In today's market, Nexreg has truly been an asset. With their quick turnaround and thorough evaluations, Nexreg has been a valued enhancement to our regulatory department. This dynamic approach to regulatory issues allows Amrep to not only meet, but also exceed, customer's expectations in a cost effective manner.
Sam Turetsky, Amrep Inc.